Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Clin Imaging. 2013 Mar-Apr;37(2):295-301. doi: 10.1016/j.clinimag.2012.07.005. Epub 2012 Aug 24.
Assess the impact of FDG-PET or PET/CT (PI) on pancreatic cancer management when added to CT or MRI (CDI).
Forty-nine patients underwent 79 PI exams. Discordant findings on PI and CDI were assessed for clinical impact.
Fifteen of 79 PI-CDI pairs were discordant. Ten of 79 PI favorably and 5 of 79 unfavorably altered management. PI favorably altered management more often when ordered for therapy monitoring compared to staging [risk ratio 13.00 (95% CI 1.77-95.30)] or restaging [risk ratio 18.5 (95% CI 2.50-137.22)].
PI favorably alters management more often when used for therapy monitoring compared to staging or restaging.
评估 FDG-PET 或 PET/CT（PI）在 CT 或 MRI（CDI）基础上加用对胰腺癌管理的影响。
49 例患者接受了 79 次 PI 检查。评估 PI 和 CDI 之间的不一致发现对临床的影响。
79 对 PI-CDI 中有 15 对不一致。79 次 PI 中有 10 次有利地改变了管理，5 次不利地改变了管理。PI 用于治疗监测时比用于分期[风险比 13.00（95%CI 1.77-95.30）]或再分期[风险比 18.5（95%CI 2.50-137.22）]更频繁地有利地改变管理。
PI 用于治疗监测时比用于分期或再分期更频繁地有利地改变管理。
